Cargando…
Biomarkers for Assessing Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus on Sodium–Glucose Cotransporter 2 Inhibitor Therapy
In the current modern era of unhealthy lifestyles, non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease and has become a serious global health problem. To date, there is no approved pharmacotherapy for the treatment of NAFLD, and necessary lifestyle changes such as weight lo...
Autores principales: | Khaznadar, Farah, Petrovic, Ana, Khaznadar, Omar, Roguljic, Hrvoje, Bojanic, Kristina, Kuna Roguljic, Lucija, Siber, Stjepan, Smolic, Robert, Bilic-Curcic, Ines, Wu, George Y., Smolic, Martina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607797/ https://www.ncbi.nlm.nih.gov/pubmed/37892698 http://dx.doi.org/10.3390/jcm12206561 |
Ejemplares similares
-
Obesity Paradox in Chronic Liver Diseases: Product of Bias or a Real Thing?
por: Curcic, Ines Bilic, et al.
Publicado: (2019) -
Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes
por: Ninčević, Vjera, et al.
Publicado: (2019) -
Preclinical Models and Promising Pharmacotherapeutic Strategies in Liver Fibrosis: An Update
por: Kolaric, Tea Omanovic, et al.
Publicado: (2023) -
Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update
por: Roguljic, Hrvoje, et al.
Publicado: (2021) -
Representation of CYP3A4, CYP3A5 and UGT1A4 Polymorphisms within Croatian Breast Cancer Patients’ Population
por: Bojanic, Kristina, et al.
Publicado: (2020)